会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • ANTINEURODEGENERATIVE ERGOLINE DERIVATIVES
    • 过氧化物衍生物衍生物
    • WO1998000424A1
    • 1998-01-08
    • PCT/EP1997002955
    • 1997-05-29
    • PHARMACIA & UPJOHN S.P.A.MANTEGANI, SergioBRAMBILLA, EnzoCARFAGNA, NicolaVARASI, Mario
    • PHARMACIA & UPJOHN S.P.A.
    • C07D457/02
    • C07D457/10A61K31/48C07D457/02
    • The present invention provides the new use in the treatment of neurodegenerative diseases with ergoline derivatives of formula (I) wherein R1 represents a hydrogen atom or a linear or branched C1-C5 alkyl or C2-C5 alkenyl group optionally substituted with a C3-C7 cycloalkyl, a hydroxy group or a R3-substituted phenyl group wherein R3 is a hydroxy or a hydroxymethyl group; R2 represents a hydrogen atom or a linear or branched C1-C5 alkyl or a C2-C5 alkenyl group optionally substituted with a hydroxy group, or a R3-substituted phenyl group wherein R3 is as above defined, or with a C1-C5 alkoxy group; the symbols -- at positions 2,3 and 8, 9 independently denote a single or double chemical bond and Z represents a group (CH2)nOH, wherein n is 0 or an integer from 1 to 3, or a group C(R4)2OH wherein R4 is a C1-C5 alkyl or a phenyl group, or a pharmaceutically acceptable salt thereof. Some compounds of formula (I) are novel. Processes for their preparation and pharmaceutical compositions containing them are also described.
    • 本发明提供了用于治疗神经变性疾病的新用途,其中式(I)的麦角灵衍生物,其中R 1表示氢原子或任选被C 3 -C 7环烷基取代的直链或支链C 1 -C 5烷基或C 2 -C 5烯基 ,羟基或R 3取代的苯基,其中R 3是羟基或羟甲基; R2表示氢原子或任选被羟基取代的直链或支链C 1 -C 5烷基或C 2 -C 5烯基,或其中R 3如上所定义的R 3取代苯基,或与C 1 -C 5烷氧基 ; 符号 - 位置2,3和8,9独立地表示单一或双重化学键,Z表示基团(CH 2)n OH,其中n为0或1至3的整数,或基团C(R 4) 其中R 4是C 1 -C 5烷基或苯基,或其药学上可接受的盐。 一些式(I)化合物是新的。 还描述了其制备方法和含有它们的药物组合物。
    • 4. 发明申请
    • N-SUBSTITUTED-2-AMINO-4-PHENYL-4-OXO-BUTANOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITORY ACTIVITY
    • N-取代-2-氨基-4-苯基-4-氧代 - 丁酸衍生物与奎宁尼-3-羟基酶抑制活性
    • WO1998009938A1
    • 1998-03-12
    • PCT/EP1997004271
    • 1997-07-31
    • PHARMACIA & UPJOHN S.P.A.VARASI, MarioGIORDANI, AntonioCINI, MassimoSPECIALE, CarmelaBIANCHETTI, Alberto
    • PHARMACIA & UPJOHN S.P.A.
    • C07C229/36
    • C07C233/47C07C311/06
    • N-substituted-2-amino-4-phenyl-4-oxo-butanoic acid compound of formula (I), wherein each of the groups X and Y is, independently, hydrogen; halogen; nitro; C1-C6 alkyl; C2-C4 alkenyl; C2-C4 alkynyl; C1-C6 alkoxy; C1-C6 alkylthio; SOR2 or SO2R2 in which R2 is C1-C6 alkyl, phenyl or benzyl; or SO2N(R3)2 in which each of the groups R3 is, independently, hydrogen, C1-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, phenyl or benzyl; R is hydroxy, -OR5 in which R5 is C1-C6 alkyl, C2-C4 alkenyl, C2-C4 alkynyl or benzyl; -N(R3)2 or -N(R3)OR3 in which each of R3 is as defined above; W is -COOR4, -COR4 or -SO2R4 in which R4 is C1-C6 alkyl, an optionally substituted C2-C4 alkenyl, an optionally substituted phenyl or benzyl; -CONHR5 or -CSNHR5 in which R5 is as defined above; trichloroacetyl; or trifluoroacetyl; or a pharmaceutically acceptable salts thereof, for use as a medicament, in particular as Kynurenine 3-hydroxylase inhibitor is disclosed.
    • 式(I)的N-取代-2-氨基-4-苯基-4-氧代 - 丁酸化合物,其中基团X和Y各自独立地为氢; 卤素; 硝基; C1-C6烷基; C 2 -C 4烯基; C2-C4炔基; C1-C6烷氧基; C1-C6烷硫基; SOR2或SO2R2,其中R2是C1-C6烷基,苯基或苄基; 或SO 2 N(R 3)2,其中基团R 3各自独立地为氢,C 1 -C 6烷基,C 2 -C 4烯基,C 2 -C 4炔基,苯基或苄基; R是羟基,-OR 5,其中R 5是C 1 -C 6烷基,C 2 -C 4烯基,C 2 -C 4炔基或苄基; -N(R3)2或-N(R3)OR3,其中R3各自如上所定义; W是-COOR 4,-COR 4或-SO 2 R 4,其中R 4是C 1 -C 6烷基,任选取代的C 2 -C 4烯基,任选取代的苯基或苄基; -CONHR 5或-CSNHR 5,其中R 5如上所定义; 三氯; 或三氟乙酰基; 或其药学上可接受的盐,用作药物,特别是Kynurenine 3-羟化酶抑制剂。